Its time to buy Opko Health (NASDAQ: OPK). The stock technical indicates it’s oversold and is in the buy zone. The Fundamental for OPKO Health are pretty strong with the company recently announcing it will start phase 2 clinical trials of Rayaldee. Coupled with that the revenue generated from covid testing done by Biorefrence labs makes Opko health a great long and short term investment. Recommended strong buy under $3.20